Login to Your Account

Eclipse Breathes New Life into Biogen Idec Cancer Platform

By Marie Powers
Staff Writer

Wednesday, April 18, 2012
Over the past year, privately held oncology biotech Eclipse Therapeutics Inc. has been assembling assets from the former cancer stem cell (CSC) franchise at Biogen Idec Inc. The newest piece in the puzzle is an exclusive worldwide license to develop and commercialize fully human antibodies discovered at Biogen Idec using phage display technology from Dyax Corp.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription